Amneal Pharmaceuticals (NASDAQ:AMRX) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX) released its earnings results on Friday. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.03), RTT News reports. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. The business had revenue of $730.52 million during the quarter, compared to analyst estimates of $708.21 million. During the same quarter in the previous year, the company posted $0.14 earnings per share. Amneal Pharmaceuticals updated its FY 2025 guidance to 0.650-0.700 EPS.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ AMRX opened at $8.67 on Friday. Amneal Pharmaceuticals has a 1-year low of $5.01 and a 1-year high of $9.48. The business has a 50-day moving average of $8.10 and a 200-day moving average of $8.32. The company has a market capitalization of $2.69 billion, a price-to-earnings ratio of -12.75 and a beta of 1.10.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on AMRX shares. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $9.00 to $12.00 in a research report on Monday, February 24th. StockNews.com downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, December 19th. Finally, Piper Sandler boosted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $10.60.

Insider Transactions at Amneal Pharmaceuticals

In other news, Director Gautam Patel sold 17,410 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total value of $139,454.10. Following the completion of the sale, the director now owns 2,031,476 shares of the company’s stock, valued at $16,272,122.76. This represents a 0.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 160,000 shares of company stock valued at $1,292,000 over the last quarter. Company insiders own 26.56% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.